China Traditional Chinese Medicine Holdings Co. Limited provided preliminary unaudited consolidated group earnings guidance for the year ended 31 December 2022. For the year, the group expects the net profit of the Group would decrease by 60% to 70% as compared to that for the same period in 2021, which is mainly caused by: shortages of published or recorded varieties of national standards and provincial standards for concentrated TCM granule which have put limits on prescription in medical ends and affects the sales for the Period; decrease in demands of some medical institutions for the Period resulting from relatively sufficient products storage of enterprise standard at the end of 2021 to cope with the implementation of the new policy; a significant increase in the production cost since the application of national standards for concentrated TCM granule, whereas price adjustment in medical ends has not yet been fully put in place; and effect arises from the newly added amortization of intangible asset of protection rights and provision for impairment of assets for the Period.